Encompass Health reiterates FY2023 guidance; Q1 rehab discharge growth strong through February

Encompass Health Corp

Reaffirms FY2023 net operating revenue guidance of $4.68B-$4.76B and adjusted EBITDA of $860M-$900M.
Reaffirms adjusted EPS guidance of $2.87-$3.16.
Inpatient rehabilitation discharge growth remained strong through February; anticipates seasonal March impact from spring break.
CEO Mark Tarr and CFO Doug Coltharp to participate in Barclays Global Healthcare Conference on March 15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.